Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

  1. FDA grants RPD designation to ProQR’s retinitis pigmentosa therapy

    ProQR has received rare paediatric disease (RPD) designation from the US Food and Drug Administration (FDA) for its retinitis pigmentosa…
    Read More…

    31 Jan
  2. Brexit viewed as negative for the pharma industry, Pharma Tech survey finds

    At 11pm GMT on 31 January the UK leaves the European Union (EU). However, under the terms of the ratified…
    Read More…

    31 Jan
  3. Q&A: talking drug quality with Valisure, the first analytical pharmacy

    In September 2019, the US Food and Drug Administration (FDA) recalled generic versions of Zantac (ranitidine) after impurities of the…
    Read More…

    30 Jan
  4. Galapagos’s SSc drug receives orphan drug designation from the EMA and FDA

    The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan drug designation to Galapagos’…
    Read More…

    30 Jan
  5. Eyepoint and Ocumension sign license agreement in China for Dexycu

    US-based Eyepoint Pharmaceuticals has signed an exclusive license agreement with Chinese Ocumension Therapeutics for the development and commercialisation of the…
    Read More…

    29 Jan
  6. Horizon 2020: a look back at flagship EU pharma projects

    Launched in 2014, Horizon 2020 is the European Union’s (EU) largest research and innovation funding programme to date. It saw…
    Read More…

    28 Jan
  7. Janssen’s esketamine nasal spray not recommended by NICE for NHS use

    The UK’s pricing regulator the National Institute for Health and Clinical Excellence (NICE) has decided to not recommend Janssen’s Spravato…
    Read More…

    28 Jan
  8. Novo Nordisk’s Saxenda not recommended for NHS use

    The UK’s National Institute for Health and Care Excellence (NICE) has decided to not recommend National Health Service (NHS) use of…
    Read More…

    27 Jan
  9. Epizyme’s Tazverik receives accelerated approval from FDA

    Epizyme has announced the US Food and Drug Administration (FDA) has granted its epithelioid sarcoma (ES) therapy Tazverik (tazemetostat) accelerated…
    Read More…

    24 Jan
  10. Manufacturing medicines in space: how astronauts will make their own drugs

    Humans, and particularly space agencies, have long dreamed of landing on Mars and transforming science fiction into science fact. However,…
    Read More…

    23 Jan
Close
Close
Close

Go Top